To cite: L'Orphelin J-M. Da

Silva A, Cabon J, et al. Immune

checkpoint inhibitor rechallenge

after immune-related adverse

events: a retrospective study

from VigiBase update in 2024

2024;14:e091708. doi:10.1136/

looking for emergent safety

signals. BMJ Open

bmjopen-2024-091708

Prepublication history

and additional supplemental

available online. To view these

online (https://doi.org/10.1136/

files, please visit the journal

bmjopen-2024-091708).

J-ML and ADS contributed

Received 26 July 2024

Accepted 01 November 2024

equally.

material for this paper are

BMJ Open Immune checkpoint inhibitor rechallenge after immune-related adverse events: a retrospective study from VigiBase update in 2024 looking for emergent safety signals

Jean-Matthieu L'Orphelin ^(b),^{1,2} Angélique Da Silva,³ Jean Cabon,² Joachim Alexandre,^{4,5} Charles Dolladille⁶

ABSTRACT

Objectives Limited information is available on the safety of a rechallenge with an immune checkpoint inhibitor (ICI) after occurrence of an immune-related adverse event (irAE). We aim to identify potential emergent safety signals. **Design** This is an update of our observational pharmacovigilance cohort study.

Setting We exanimated individual case safety reports from the WHO database VigiBase.

Participants We included all individual case safety reports with ICI and rechallenged ICI.

Interventions We identified that incident irAE cases using the Medical Dictionary for Regulatory Activities V.26.1 related with at least one ICI administration were systematically collected until 1 March 2024.

Primary and secondary outcome measures The primary outcome was the recurrence rate (expressed as a percentage with its 95% CI) of the initial irAE postrechallenge with the same ICI.

Results We identified 1016 irAEs cases from ICI rechallenges. Of these, 323 irAEs recurrences occurred (31.8%, 95% Cl 28.1 to 34.0). The most common postrechallenge irAEs were nephritis (recurrence rate: 50%, 95% Cl 25 to 75), skin irAEs (44%, 95% Cl 31 to 58) and colitis (39%, 95% Cl 33 to 44). **Conclusions** In this updated, largest cohort study on rechallenge (NCT04696250), we observed a 31.8% recurrence rate of the same irAE postrechallenge with the

recurrence rate of the same irAE postrechallenge with the same ICI, building on our previous findings. **Trial registration number** NCT04696250.

Check for updates

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Jean-Matthieu L'Orphelin; jean.matthieu.lorphelin@gmail. com

INTRODUCTION

The advent of immune checkpoint inhibitors (ICIs) has profoundly transformed oncological therapeutics over recent years.¹ Sustained therapeutic responses have been documented, such as in metastatic melanoma, where overall survival (OS) at 6.5 years reaches 42% and 49% for nivolumab and the combination of nivolumab and ipilimumab, respectively.² These substantial clinical benefits at the metastatic stage have led to the

STRENGTHS AND LIMITATIONS OF THIS STUDY

- \Rightarrow Largest cohort of immune-related adverse event.
- \Rightarrow International.
- \Rightarrow Emergent safety signals.
- \Rightarrow Retrospective.
- ⇒ No Common Terminology Criteria for Adverse Events grade differentiation.

broadening implementation of ICIs across the therapeutic spectrum, including in the text adjuvant³ and neoadjuvant settings.⁴ Now endorsed for the management of all solid cancers, ICIs have indeed been conceded as the contemporary standard of care. This efficacy is paradoxically mediated by the **E** same mechanism that prompts immunerelated adverse events (irAEs), stemming ≥ from systemic immune activation.^{5 6} Up to 80% of patients may encounter any-grade irAEs, with Common Terminology Criteria for Adverse Events grades 3–5 irAEs affecting **9** 8%.⁷ Although the majority of irAEs abate on cessation of ICI therapy and corticosteroid administration, their influence on oncological outcomes remains a subject of ongoing debate.⁸ For severe or corticoresistant irAEs, the introduction of immunomodulatory agents is recommended, adhering to established guidelines.⁹ The term 'rechallenge' is frequently used to describe the resumption **g** of an ICI following a hiatus required for the irAE resolution.¹⁰ With ICIs being introduced earlier in the disease trajectory and concomitant with OS extension, patients frequently face the prospect of multiple exposures to ICIs during their lifetime. Therefore, understanding the safety of rechallenge is critical, in the context of limited alternative treatments. Our study is an expansive cohort

of our initial recruitment¹¹ in which we documented a recurrence rate of 28.8% for the original irAE on rechallenge, noting particularly high recurrence rates for irAEs such as colitis and pneumonitis. Herein, we extend our prior inquiry and provide an updated analysis on irAE recurrence post-rechallenge.

MATERIALS AND METHODS

Data were sourced from VigiBase, the WHO pharmacovigilance database managed by the Uppsala Monitoring Centre (Sweden).

Incident irAE cases related with at least one ICI administration were systematically collected, until 1 March 2024. We identified irAEs using Preferred Terms from the Medical Dictionary for Regulatory Activities V.26.1. ICI therapies included anti-PD-1 antibodies (cemiplimab, dostarlimab, nivolumab, pembrolizumab, retifanlimab), anti-PD-L1 antibodies (atezolizumab, avelumab, durvalumab), anti-CTLA-4 antibodies (ipilimumab, tremelimumab), and anti-LAG3 therapy (relatlimab). ICI regimen types were classified as anti-PD(L)-1 monotherapy, anti-CTLA-4 monotherapy, combined anti-PD(L)-1/anti-CTLA-4 therapy and combined anti-PD(L)-1/anti-LAG3 therapy. For the initial irAE event, a comprehensive collection of administrative, demographic, drug- and irAE-specific data were pursued, encompassing parameters such as patient age, sex, drug indication, rechallenge, irAE type and severity, and irAEassociated mortality. Each irAE was designated as 'serious' or 'non-serious' in accordance with WHO criteria, and cases were discerned as either initial or updated with progressive follow-up details.

The primary outcome was the reported irAE recurrence rate postrechallenge with the same ICI agent, ascertained among informative rechallenge cases. Exploratory secondary outcomes were factors presumptively associated with irAE recurrence postrechallenge, which encompassed ICI regimens.

Statistical analyses were consistent with our princeps article.¹¹ Reported recurrence rates were denoted as percentages, dividing the number of irAE recurrence cases by the number of informative rechallenge cases. The 95% CIs for binomial proportions were estimated applying the Agresti-Coull approach. Qualitative variables were reported as frequencies and percentages, while quantitative variables were reported as medians with IQRs. Comparisons between rechallenge and non-rechallenge cohorts were conducted using the χ^2 test or Fisher's exact test for qualitative data, alongside the unpaired Kruskal-Wallis test for quantitative data. Univariate logistic regression was employed to compute reporting ORs with 95% CIs. Statistical significance was ascertained through the Wald test, where a p value less than 0.05 was deemed significant. Statistical computations were performed using the R software for Windows, V.4.3.2 (R Project for uses related Statistical Computing).

The ethics committee at Caen University Hospital deemed formal review and consent procedures unnecessary due to the utilisation of anonymised data within this study.

RESULTS

The study encompassed 48380 cases of irAEs associated with ICI administrations, which approximates a two-fold

drug reaction	NO. OF	(95%CI), %
Diabetes	30	7 (1-22)
Adrenal	76	16 (9-26)
Hypophysitis	42	17 (8-31)
Neurological	39	21 (11-36)
Thyroiditis	119	22 (15-30)
Mucositis	20	25 (11-47)
Uveitis	16	25 (10-50)
Hematological	15	27 (10-52)
Pancreatitis	25	28 (14-48)
Pneumonitis	187	29 (23-36)
Myositis	17	29 (13-53)
Hepatitis	85	32 (23-42)
Myocarditis	15	33 (15-58)
Arthritis	74	35 (25-47)
Colitis	288	39 (33-44)
Skin	50	44 (31-58)
Nephritis	12	50 (25-75)



Figure 1 Recurrence rate of immune-related adverse events (irAEs) categorised by the initial affected site updated in March 2024.

increase compared with our inaugural study. A subset of 18753 cases underwent an ICI rechallenge post-irAE, and 1016 cases had available data on irAE recurrence. Of these, 323 subjects were notified with a recurrence, equating to a 31.8% recurrence rate (95% CI 28.1 to 34.0). Within informative cases, 117 (36.0%) were female, and the modal age group was 65-74 years (n=116, 44.1%). Factors associated with the recurrence of the initial irAE are detailed in supplementary material.

IrAE recurrence was significantly associated with ICI regimens, with a reporting OR of 0.70 (95% CI, 0.50 to 0.98) for anti-PD(L)1 monotherapy, 0.88 (95%CI, 0.36 to 2.15) for anti-CTLA-4 monotherapy, and 1.52 (95%CI, 1.07 to 2.17) for combination therapy.

The three highest recurrence rates were found for nephritis (50%, 95% CI 25 to 75), skin irAEs (44%, 95%) CI 31 to 58) and colitis (39%, 95% CI 33 to 44) as shown in figure 1. Details are provided in supplementary material.

DISCUSSION

The safety profile of postrechallenge ICIs remains a relatively terra incognita within the field. Our study, which includes a cohort of 18753 rechallenge cases-with 1016 yielding informative data-substantially enlarges on the evidence base previously established.¹¹ We observed 31.8% recurrence of the same irAEs postrechallenge, corroborating both current literature and our previous findings.¹¹

Reflecting on retrospective analyses, such as one involving 40 rechallenged patients where 17 (42.5%)experienced a recurrence of the same irAE and 5 (12.5%)manifested a novel irAE,¹² our findings are aligned. Moreover, a meta-analysis surveying 789 cases documented incidences of all-grade and high-grade irAEs at 34.2% and 11.7%, respectively.¹³ Gastrointestinal irAEs were associated with higher high-grade irAEs recurrence, while initial anti-PD(L)-1 correlated with lower recurrence. Despite an augmented incidence of all-grade irAEs postrechallenge (OR, 3.81; 95% CI 2.15 to 6.74; p<0.0001), the incidence of high-grade irAEs was not significantly different (p>0.05); hence, the tolerance profile persists as acceptable.

The present inquiry has additionally surfaced novel insights pertaining to nephritis and myocarditis, which were absent from our preceding study.¹¹ The recurrence rate of nephritis was 50%, which overshadows prior estimates documented in the literature.¹⁴ Our analysis, comprising 12 cases of rechallenged nephritis, may suffer from insufficient statistical power. Additionally, we were unable to assess the potential influence of the temporal interval between the initial irAE and subsequent rechallenge, a factor that could affect nephritis recurrence risk, thereby constraining our ability to derive conclusive insights on risk modulation of nephritis recurrence. Myocarditis, a relatively infrequent but severe irAE,¹⁵ portrayed a 33% recurrence rate postrechallenge in our cohort, underscoring the necessity for careful

<page-header><page-header><text><text><text><text><text><text><text><text><text><text><text><text>

Data availability statement Data are available upon reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information. Data are available on request to CD, corresponding author.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Jean-Matthieu L'Orphelin http://orcid.org/0000-0002-5680-7888

REFERENCES

- Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018;378:1277–90.
- 2 Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. JCO 2022;40:127–37.
- 3 Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med 2017;377:1824–35.

- 4 Patel SP, Othus M, Chen Y, et al. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med 2023;388:813–23.
- 5 Boutros C, Tarhini A, Routier E, *et al.* Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. *Nat Rev Clin Oncol* 2016;13:473–86.
- 6 Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. *Transl Lung Cancer Res* 2015;4:560–75.
- 7 Lemiale V, Meert A-P, Vincent F, *et al.* Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know? *Ann Intensive Care* 2019;9:25.
- 8 Tokunaga A, Sugiyama D, Maeda Y, et al. Selective inhibition of low-affinity memory CD8⁺ T cells by corticosteroids. J Exp Med 2019;216:2701–13.
- 9 Available: https://www.nccn.org/immunotherapy-tool/pdf/NCCN_ Immunotherapy_Teaching_Monitoring_Tool.pdf [accessed 13 Oct 2023]
- 10 Allouchery M, Beuvon C, Pérault-Pochat M-C, et al. Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review. Cancers (Basel) 2022;14:955.
- 11 Dolladille C, Ederhy S, Sassier M, et al. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol 2020;6:865–71.
- 12 Simonaggio A, Michot JM, Voisin AL, et al. Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol 2019;5:1310–7.
- 13 Zhao Q, Zhang J, Xu L, et al. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis. Front Immunol 2021;12:730320.
- 14 Rao Ullur A, Côté G, Pelletier K, et al. Immunotherapy in oncology and the kidneys: a clinical review of the evaluation and management of kidney immune-related adverse events. *Clin Kidney J* 2023;16:939–51.
- 15 Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol 2018;71:1755–64.

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies